fashion -WSS

fashion

author：knowledge 2025-10-01 15:30:20 - browse：96919

Senate Health, Education, Labor, and Pensions Committee Chairman Bernie Sanders looks at Moderna CEO Stephane Bancel as he testifies. Sitting next to Sanders, ranking member Sen. Bill Cassidy looks down – policy coverage from STAT — Committee Ranking Republican Bill Cassidy (La.) and Chairman Bernie Sanders (I-Vt.) Chip Somodevilla/Getty Images

WASHINGTON – The Senate health committee on Thursday passed a package of bills aimed at speeding generic drug competition and reining in drug middlemen business practices. But they failed to pass an ambitious reform to the pharmacy benefit manager sector, despite strong bipartisan support for it.

Chairman Bernie Sanders (I-Vt.) is pursuing the drug pricing reforms at the behest of Senate Majority Leader Chuck Schumer (D-N.Y.), who wants to hold a floor vote on an even bigger package of health bills later this year. The markup came just a day after the same panel held a major hearing on PBM and drugmakers’ role in high insulin prices.

It’s not clear when the Senate would take up that package, and while the package is bipartisan, it’s not clear whether it has enough support among House Republicans to pass in that chamber. There are a few, tamer PBM bills that the House Energy and Commerce Committee is expected to mark up May 17, but there is no indication that Senate and House lawmakers are coordinating on PBM legislation.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： WHO recommends dropping component of many flu vaccines

hotspot

WSS

Biotech reporter’s notebook: A sunnier mood at JPM 2024

Paxlovid should be available without a positive Covid test

Heart disease and mental health: A look at cardiac psychology

Paxlovid should be available without a positive Covid test

The SUPPORT Act is critical to fighting the opioid crisis

Why liver experts renamed NASH to MASH, and NAFLD to MASLD

focus

fashion

focus

The cancer drug shortage isn’t new — and neither are the solutions

JPM 2024: FogPharma’s CEO unveils ‘contrarian’ plan in oncology

After affirmative action ruling, medical educators look to 'holistic review'

Paxlovid should be available without a positive Covid test

Psychedelics group wrestles with new pharma identity

Heart disease and mental health: A look at cardiac psychology

Trump demands the U.S. pay no more for drugs than other countries … again

Biotech reporter’s notebook: A sunnier mood at JPM 2024

George Santos makes 1st court appearance after pleading not guilty to 13 counts

New Medicare drug pricing powers could soon be upended in court

knowledge

Idaho abortion case may prompt more restrictions in other states

Health tech startups drop sharply from 2021 highs

Paxlovid should be available without a positive Covid test

FDA advisers vote against ALS treatment from BrainStorm

Why liver experts renamed NASH to MASH, and NAFLD to MASLD

Fauci’s Covid grilling leads GOP to weigh foreign research rules

explore

hotspot

hotspot

focus